Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
Atherosclerosis
; 224(2): 454-6, 2012 Oct.
Article
em En
| MEDLINE
| ID: mdl-22892323
ABSTRACT
OBJECTIVE:
To assess the mechanism of long-term LDL-C-lowering effect of ezetimibe-plus-statin.METHODS:
Coronary artery disease patients whose LDL-C ≥ 70 mg/dL after treatment with atorvastatin 10 mg/day or rosuvastatin 2.5 mg/day were randomly assigned to receive ezetimibe 10 mg/day + statin (n = 78) or double-dose statin (n = 72) for 52 weeks.RESULTS:
Greater LDL-C reduction was observed and maintained until 52 weeks in ezetimibe-plus-statin, while LDL-C levels re-increased after 12 weeks in double-dose statin. Although lathosterol/TC increased, campesterol/TC decreased more in ezetimibe-plus-statin. In contrast, lathosterol/TC unchanged and campesterol/TC increased, increasing campesterol/lathosterol ratio for 52 weeks in double-dose statin. Plasma PCSK9 levels were higher in double-dose statin than in ezetimibe-plus-statin at 12 weeks, but similar at 52 weeks.CONCLUSION:
Although the difference in PCSK9 between 2 groups was transient, that in both campesterol and lathosterol persisted until 52 weeks. These results demonstrated simultaneous inhibition of cholesterol absorption and synthesis provides stable and greater decrease in LDL-C levels.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pirimidinas
/
Pirróis
/
Sulfonamidas
/
Azetidinas
/
Doença da Artéria Coronariana
/
Inibidores de Hidroximetilglutaril-CoA Redutases
/
Fluorbenzenos
/
Ácidos Heptanoicos
/
LDL-Colesterol
/
Anticolesterolemiantes
Tipo de estudo:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País como assunto:
Asia
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article